Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions: hepatocellular adenoma review. J Gastroenterol Hepatol. 2011;26(1):28–35. doi:10.1111/j.1440-1746.2010.06502.x
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Bagante F, Sahara K, et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: a comprehensive assessment of the current BCLC classification. Ann Surg Oncol. 2019;26(11):3693–3700. doi:10.1245/s10434-019-07580-9
   PubMed Web of Science ®Google Scholar
• Ligat G, Schuster C, Baumert TF. Hepatitis B virus core variants, liver fibrosis, and Hepatocellular Carcinoma. Hepatology. 2019;69(1):5–8. doi:10.1002/hep.30231
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Han W, Ding P, Xu M, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validation. Genomics. 2003;81(6):609–617. doi:10.1016/S0888-7543(03)00095-8
   PubMed Web of Science ®Google Scholar
• Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549(7670):101–105. doi:10.1038/nature23643
   PubMed Web of Science ®Google Scholar
• Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 2018;35:233–243. doi:10.1016/j.ebiom.2018.08.012
   PubMed Web of Science ®Google Scholar
• Cancer research advance in CKLF-like MARVEL transmembrane domain containing member family (review). Available from: https://pubmed.ncbi.nlm.nih.gov/27356683/. Accessed April 4, 2023.
   Google Scholar
• Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106–110. doi:10.1038/nature23669
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Wang X, et al. CMTM family and gastrointestinal tract cancers: a comprehensive review. Cancer Manag Res. 2022;14:1551–1563. doi:10.2147/CMAR.S358963
   PubMed Web of Science ®Google Scholar
• W HAN, Y LOU, Tang J, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001;357(1):127–135. doi:10.1042/bj3570127
   PubMedGoogle Scholar
• Shi S, Rui M, Han W, et al. CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. Int J Biochem Cell Biol. 2005;37(8):1633–1640. doi:10.1016/j.biocel.2004.04.028
   PubMed Web of Science ®Google Scholar
• Liu B, Li H, Fu W, et al. CMTM3 presents a secreted form released via exosomes. ABBS. 2016;48(6):584–586. doi:10.1093/abbs/gmw029
   Google Scholar
• Li H, Guo X, Shao L, et al. CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway. BMB Rep. 2010;43(3):182–187. doi:10.5483/BMBRep.2010.43.3.182
   PubMed Web of Science ®Google Scholar
• Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017;552(7683):126–131. doi:10.1038/nature24678
   PubMed Web of Science ®Google Scholar
• Delic S, Thuy A, Schulze M, et al. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets. Genes Chromosomes Cancer. 2015;54(7):433–443. doi:10.1002/gcc.22255
   PubMed Web of Science ®Google Scholar
• Sánchez-Pulido L, Martín-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in membrane apposition events. Trends Biochem Sci. 2002;27(12):599–601. doi:10.1016/s0968-0004(02)02229-6
   PubMed Web of Science ®Google Scholar
• Cai X, Deng J, Ming Q, Cai H, Chen Z. Chemokine-like factor 1: a promising therapeutic target in human diseases. Exp Biol Med. 2020;245(16):1518–1528. doi:10.1177/1535370220945225
   Web of Science ®Google Scholar
• Liu DD, Song XY, Yang PF, et al. Progress in pharmacological research of chemokine like factor 1 (CKLF1). Cytokine. 2018;102:41–50. doi:10.1016/j.cyto.2017.12.002
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu L, Zhou Y, et al. CKLF1 enhances inflammation-mediated carcinogenesis and prevents doxorubicin-induced apoptosis via IL6/STAT3 signaling in HCC. Clin Cancer Res. 2019;25(13):4141–4154. doi:10.1158/1078-0432.CCR-18-3510
   PubMed Web of Science ®Google Scholar
• Chen C, Ai Q-D, Wei Y-H, et al. Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux. J Ethnopharmacol. 2021;264:113388. doi:10.1016/j.jep.2020.113388
   PubMed Web of Science ®Google Scholar
• Wu K, Li X, Gu H, Yang Q, Liu Y, Wang L. Research advances in CKLF-like MARVEL transmembrane domain-containing family in non-small cell lung cancer. Int J Biol Sci. 2019;15(12):2576–2583. doi:10.7150/ijbs.33733
   PubMed Web of Science ®Google Scholar
• Song X, Zhang S, Tian R, et al. Expression and clinical significance of CMTM1 in hepatocellular carcinoma. Open Med. 2021;16(1):217–223. doi:10.1515/med-2021-0221
   Web of Science ®Google Scholar
• Si J, Zhang P, Tian D, et al. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. World J Surg Oncol. 2017;15(1):34. doi:10.1186/s12957-016-1094-z
   PubMed Web of Science ®Google Scholar
• Cao L, Yang C, Zhu B, et al. A novel protein CMTM1-v5 specifically induced human lymphoma cells apoptosis in vitro and in vivo. Exp Cell Res. 2019;385(1):111623. doi:10.1016/j.yexcr.2019.111623
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang G, Zhang Y, et al. CMTM1_v17 is a novel potential therapeutic target in breast cancer. Oncol Rep. 2014;32(5):1829–1836. doi:10.3892/or.2014.3429
   PubMed Web of Science ®Google Scholar
• Liang Z, Xie J, Huang L, et al. Comprehensive analysis of the prognostic value of the chemokine-like factor-like MARVEL transmembrane domain-containing family in gastric cancer. J Gastrointest Oncol. 2021;12(2):388–406. doi:10.21037/jgo-21-78
   PubMed Web of Science ®Google Scholar
• Chen S, Hu Q, Chen H, et al. Identification of serum CMTM2 as a potential biomarker for HBV-related disorders. Dis Markers. 2020;2020:2032056. doi:10.1155/2020/2032056
   PubMed Web of Science ®Google Scholar
• Choi JH, Kim YB, Ahn JM, et al. Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer. Exp Mol Med. 2018;50(4):1–11. doi:10.1038/s12276-017-0009-6
   Web of Science ®Google Scholar
• van Doorn R, Slieker RC, Boonk SE, et al. Epigenomic analysis of sézary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers. J Invest Dermatol. 2016;136(9):1876–1884. doi:10.1016/j.jid.2016.03.042
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang S, Tan S, et al. Downregulated CMTM2 poses potential clinical significance in Hepatocellular Carcinoma. DNA Cell Biol. 2020;39(4):683–689. doi:10.1089/dna.2019.5237
   PubMed Web of Science ®Google Scholar
• Zhang S, Tian R, Bei C, et al. Down-regulated CMTM2 promotes epithelial-mesenchymal transition in Hepatocellular Carcinoma. OTT. 2020;13:5731–5741. doi:10.2147/OTT.S250370
   Google Scholar
• Wang Y, Li J, Cui Y, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69(12):5194–5201. doi:10.1158/0008-5472.CAN-08-3694
   PubMed Web of Science ®Google Scholar
• Wu J, Li L, Wu S, Xu B. CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value. Cancer Biol Med. 2020;17(3):528–542. doi:10.20892/j.issn.2095-3941.2020.0032
   PubMed Web of Science ®Google Scholar
• Hu F, Yuan W, Wang X, et al. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells. Clin Transl Oncol. 2015;17(8):632–639. doi:10.1007/s12094-015-1288-9
   PubMed Web of Science ®Google Scholar
• Li Z, Xie J, Wu J, et al. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS One. 2014;9(2):e88965. doi:10.1371/journal.pone.0088965
   PubMed Web of Science ®Google Scholar
• Su Y, Lin Y, Zhang L, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2014;105(1):26–34. doi:10.1111/cas.12304
   PubMed Web of Science ®Google Scholar
• Han T, Shu T, Dong S, et al. Chemokine-like factor-like MARVEL transmembrane domain-containing 3 expression is associated with a favorable prognosis in esophageal squamous cell carcinoma. Oncol Lett. 2017;13(5):2982–2988. doi:10.3892/ol.2017.5837
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ma Z, Li Z, et al. CMTM3 overexpression predicts poor survival and promotes proliferation and migration in pancreatic cancer. J Cancer. 2021;12(19):5797–5806. doi:10.7150/jca.57082
   PubMed Web of Science ®Google Scholar
• Lu M, Huang Y, Sun W, Li P, Li L, Li L. miR-135b-5p promotes gastric cancer progression by targeting CMTM3. Int J Oncol. 2018;52(2):589–598. doi:10.3892/ijo.2017.4222
   PubMed Web of Science ®Google Scholar
• Yuan W, Li T, Mo X, et al. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway. Oncotarget. 2016;7(20):29507–29519. doi:10.18632/oncotarget.8789
   PubMedGoogle Scholar
• Yuan W, Wei F, Ouyang H, et al. CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway. Cancer Cell Int. 2021;21(1):510. doi:10.1186/s12935-021-02159-5
   PubMed Web of Science ®Google Scholar
• Yuan W, Liu B, Wang X, et al. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer. Cancer Lett. 2017;386:77–86. doi:10.1016/j.canlet.2016.11.015
   PubMed Web of Science ®Google Scholar
• Li S, Gao P, Dai X, Ye L, Wang Z, Cheng H. New prognostic biomarker CMTM3 in low grade glioma and its immune infiltration. Ann Transl Med. 2022;10(4):206. doi:10.21037/atm-22-526
   PubMed Web of Science ®Google Scholar
• Li W, Zhang S. CKLF-like MARVEL transmembrane domain-containing member 3 (CMTM3) inhibits the proliferation and tumorigenisis in Hepatocellular Carcinoma cells. Oncol Res. 2017;25(2):285–293. doi:10.3727/096504016X14732523471442
   PubMed Web of Science ®Google Scholar
• Yu ZL, Zhu ZM. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma. Bioengineered. 2021;12(1):1708–1724. doi:10.1080/21655979.2021.1923381
   PubMed Web of Science ®Google Scholar
• Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–1161. doi:10.1038/nmat4997
   PubMed Web of Science ®Google Scholar
• Bei C, Zhang Y, Wei R, et al. Clinical significance of CMTM4 expression in hepatocellular carcinoma. Onco Targets Ther. 2017;10:5439–5443. doi:10.2147/OTT.S149786
   PubMed Web of Science ®Google Scholar
• Kittler R, Putz G, Pelletier L, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature. 2004;432(7020):1036–1040. doi:10.1038/nature03159
   PubMed Web of Science ®Google Scholar
• Li M, Guo H, Wang Q, et al. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Cancer Lett. 2020;490:20–30. doi:10.1016/j.canlet.2020.06.009
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang S, Tan S, et al. Expression of CMTM4 shows clinical significance in lung cancer. Transl Cancer Res. 2020;9(10):6214–6220. doi:10.21037/tcr-20-1254
   PubMed Web of Science ®Google Scholar
• Dai X, Bu X, Gao Y, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021;81(11):2317–2331.e6. doi:10.1016/j.molcel.2021.03.037
   PubMed Web of Science ®Google Scholar
• Zhou L, Lu H, Zeng F, et al. Constructing a new prognostic signature of gastric cancer based on multiple data sets. Bioengineered. 2021;12(1):2820–2835. doi:10.1080/21655979.2021.1940030
   PubMed Web of Science ®Google Scholar
• Kong J,Tan S. CMTM4与肿瘤的研究进展 [Advances in the study of CMTM4 and tumors]. Chinese Journal of Oncology Prevention and Treatment. 2019;11(1):85–88. Chinese.
   Google Scholar
• Kong J. CMTM4在肝细胞癌发生发展中的作用及机制研究 [The Role and Mechanism of CMTM4 in the Development of Hepatocellular Carcinoma]. China: Guilin Medical University; 2020. Chinese.
   Google Scholar
• Shao L, Cui Y, Li H, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in Carcinoma cell lines. Clin Cancer Res. 2007;13(19):5756–5762. doi:10.1158/1078-0432.CCR-06-3082
   PubMed Web of Science ®Google Scholar
• Chen Z, Cui N, Zhao J-S, et al. Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances. Eur J Histochem. 2021;65(1). doi:10.4081/ejh.2021.3173
   Web of Science ®Google Scholar
• Yuan Y, Sheng Z, Liu Z, et al. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells. J Cancer. 2020;11(13):3762–3770. doi:10.7150/jca.42314
   PubMed Web of Science ®Google Scholar
• Li L, Hu Y, Chen D, et al. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway. Mol Med Rep. 2022;25(1):1–10. doi:10.3892/mmr.2021.12533
   PubMed Web of Science ®Google Scholar
• Chen F, Li Y, Qin N, et al. RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer. J Biomed Res. 2020;34(2):129–138. doi:10.7555/JBR.34.20190111
   PubMed Web of Science ®Google Scholar
• Bei C, Tan C, Zhu X, Wang Z, Tan S. Association between polymorphisms in CMTM family genes and Hepatocellular Carcinoma in Guangxi of China. DNA Cell Biol. 2018;37(8):691–696. doi:10.1089/dna.2018.4274
   PubMed Web of Science ®Google Scholar
• Xu G, Dang C. CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell Int. 2017;17(1):113. doi:10.1186/s12935-017-0485-8
   PubMedGoogle Scholar
• Zhao Y, Zhang M, Pu H, Guo S, Zhang S, Wang Y. Prognostic implications of pan-cancer CMTM6 expression and its relationship with the immune microenvironment. Front Oncol. 2020;10:585961. doi:10.3389/fonc.2020.585961
   PubMed Web of Science ®Google Scholar
• Liu Y, Li X, Zhang H, Zhang M, Wei Y. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. Oncogene. 2021;40(12):2230–2242. doi:10.1038/s41388-021-01689-6
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhao S, Wang X. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer. Cancer Cell Int. 2021;21(1):78. doi:10.1186/s12935-020-01734-6
   PubMed Web of Science ®Google Scholar
• Nishi M, Shimada M, Yoshikawa K, et al. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer. J Med Invest. 2021;68(3.4):362–367. doi:10.2152/jmi.68.362
   PubMedGoogle Scholar
• Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology. 2020;10(1):1864909. doi:10.1080/2162402X.2020.1864909
   PubMed Web of Science ®Google Scholar
• Zhu X, Qi G, Li C, et al. Expression and clinical significance of CMTM6 in Hepatocellular Carcinoma. DNA Cell Biol. 2019;38(2):193–197. doi:10.1089/dna.2018.4513
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhu Y, Yang J, et al. CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma. Cell Death Dis. 2022;13(3):251. doi:10.1038/s41419-022-04676-1
   PubMed Web of Science ®Google Scholar
• Muranushi R, Araki K, Yokobori T, et al. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci. 2021;112(8):3314–3323. doi:10.1111/cas.15004
   PubMed Web of Science ®Google Scholar
• Huang X, Xiang L, Wang B, et al. CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells. J Transl Med. 2021;19(1):120. doi:10.1186/s12967-021-02787-5
   PubMed Web of Science ®Google Scholar
• Imamovic D, Vranic S. Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. Ann Transl Med. 2017;5(23):467. doi:10.21037/atm.2017.09.32
   PubMed Web of Science ®Google Scholar
• Li H, Liu YT, Chen L, et al. CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma. Mol Carcinog. 2021;60(8):556–566. doi:10.1002/mc.23323
   PubMed Web of Science ®Google Scholar
• Wang Z, Peng Z, Liu Q, et al. Co-expression with membrane CMTM6/4 on tumor epithelium enhances the prediction value of PD-L1 on anti-PD-1/L1 therapeutic efficacy in gastric adenocarcinoma. Cancers. 2021;13(20):5175. doi:10.3390/cancers13205175
   PubMed Web of Science ®Google Scholar
• Yugawa K, Itoh S, Yoshizumi T, et al. CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in Hepatocellular Carcinoma. Hepatol Commun. 2021;5(2):334–348. doi:10.1002/hep4.1643
   PubMed Web of Science ®Google Scholar
• Chui NNQ, Cheu JWS, Yuen VWH, et al. Inhibition of CMTM4 sensitizes cholangiocarcinoma and Hepatocellular Carcinoma to T cell–mediated antitumor immunity through PD‐L1. Hepatol Commun. 2022;6(1):178. doi:10.1002/hep4.1682
   PubMed Web of Science ®Google Scholar
• Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F. CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. Ann Transl Med. 2018;6(3):54. doi:10.21037/atm.2017.11.26
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bravo V, Maciejowski J, Corona J, et al. Nuclear pores protect genome integrity by assembling a premitotic and Mad1-dependent anaphase inhibitor. Cell. 2014;156(5):1017–1031. doi:10.1016/j.cell.2014.01.010
   PubMed Web of Science ®Google Scholar
• Lu C, Zhao Y, Wang J, et al. Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7/EGFR/AKT axis. Mol Med. 2021;27(1):78. doi:10.1186/s10020-021-00338-8
   PubMed Web of Science ®Google Scholar
• Xiao M, Hasmim M, Lequeux A, et al. Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer. Cancers. 2021;13(5):1165. doi:10.3390/cancers13051165
   PubMed Web of Science ®Google Scholar
• Liu Q, Su Y, Jiang GC, et al. Change of CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non-small cell lung cancer. Chin Med J. 2013;126(16):3006–3012.
   PubMed Web of Science ®Google Scholar
• Liu B, Lu Y, Zhang T, et al. CMTM7 as a novel molecule of ATG14L-Beclin1-VPS34 complex enhances autophagy by Rab5 to regulate tumorigenicity. Cell Commun Signal. 2021;19(1):77. doi:10.1186/s12964-021-00720-3
   PubMed Web of Science ®Google Scholar
• Zm H, Pl L, Y P, et al. Overexpression of CMTM7 inhibits cell growth and migration in liver cancer. Kaohsiung J Med Sci. 2019;35(6). doi:10.1002/kjm2.12058
   Web of Science ®Google Scholar
• Both J, Krijgsman O, Bras J, et al. Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma. PLoS One. 2014;9(12):e115835. doi:10.1371/journal.pone.0115835
   PubMed Web of Science ®Google Scholar
• Jin C, Wang Y, Han W, et al. CMTM8 induces caspase-dependent and -independent apoptosis through a mitochondria-mediated pathway. J Cell Physiol. 2007;211(1):112–120. doi:10.1002/jcp.20914
   PubMed Web of Science ®Google Scholar
• Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985;325(8425):366–368. doi:10.1016/s0140-6736(85)91386-8
   Google Scholar
• Wu J, Sun Y, Xiong Z, et al. Influence of CMTM8 polymorphisms on lung cancer susceptibility in the Chinese Han population. Pharmacogenet Genomics. 2021;31(4):89–95. doi:10.1097/FPC.0000000000000426
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang C, Ning Z, et al. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Ann Transl Med. 2021;9(1):42. doi:10.21037/atm-20-1013
   PubMed Web of Science ®Google Scholar
• Yan M, Zhu X, Qiao H, Zhang H, Xie W, Cai J. Downregulated CMTM8 correlates with poor prognosis in gastric cancer patients. DNA Cell Biol. 2021;40(6):791–797. doi:10.1089/dna.2021.0110
   PubMed Web of Science ®Google Scholar
• Zeng X, Ma X, Guo H, et al. MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8. Bioengineered. 2021;12(2):10126–10135. doi:10.1080/21655979.2021.2000741
   PubMed Web of Science ®Google Scholar
• Zhang W, Mendoza MC, Pei X, et al. Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem. 2012;287(15):11850–11858. doi:10.1074/jbc.M111.258236
   PubMed Web of Science ®Google Scholar
• Zhang W, Qi H, Mo X, et al. CMTM8 is frequently downregulated in multiple solid tumors. Appl Immunohistochem Mol Morphol. 2017;25(2):122–128. doi:10.1097/PAI.0000000000000274
   PubMedGoogle Scholar
• Liu LL, Zhang SW, Chao X, et al. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70(2):417–429. doi:10.1007/s00262-020-02691-9
   PubMed Web of Science ®Google Scholar